Search Clinical Trials
Sponsor Condition of Interest |
---|
Neurobehavioral Mechanisms of Cocaine Choice
Joshua A. Lile, Ph.D.
Cocaine Use Disorder
The objective of this protocol is to use a drug-vs-money choice task, reinforcement
learning modeling and fMRI to determine the neurobehavioral and neurobiological
decision-making "profile" associated with the decision to take cocaine and the reduced
cocaine choice that occurs during behavioral and1 expand
The objective of this protocol is to use a drug-vs-money choice task, reinforcement learning modeling and fMRI to determine the neurobehavioral and neurobiological decision-making "profile" associated with the decision to take cocaine and the reduced cocaine choice that occurs during behavioral and pharmacological interventions. Type: Interventional Start Date: Jan 2021 |
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
Ad scientiam
Myasthenia Gravis
ME&MG is a standalone software (digital solution) running on patients smartphones,
connected to a web portal for physicians. It is intended to be used as an unsupervised
digital self-assessment tool for the monitoring of disabilities in patients living with
MG.
ME&MG contains digital active tests1 expand
ME&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders. The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction. Type: Interventional Start Date: Jan 2024 |
iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction
SI-BONE, Inc.
Sacroiliac Joint Dysfunction
Sacroiliac; Fusion
Sacroiliac Disorder
Sacroiliac Joint Pain
STACI is a prospective, multicenter, study of SIJ fusion using the iFuse TORQ implant
system. expand
STACI is a prospective, multicenter, study of SIJ fusion using the iFuse TORQ implant system. Type: Interventional Start Date: May 2023 |
A mHealth System for Patients With POTS
Jami Warren
POTS - Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome (POTS) affects approximately 500,000 - 3
million Americans. This number will only increase due to the large number of patients
experiencing POTS due to "long COVID." POTS patients experience several symptoms,
including tachycardia, palpitations, dizziness,1 expand
Postural Orthostatic Tachycardia Syndrome (POTS) affects approximately 500,000 - 3 million Americans. This number will only increase due to the large number of patients experiencing POTS due to "long COVID." POTS patients experience several symptoms, including tachycardia, palpitations, dizziness, and pre-syncope or syncope, among others. POTS can be very debilitating and not only affect patients physically but also emotionally and financially. It takes an average of four years and seven doctors for POTS patients to achieve a diagnosis and it is often a frustrating and negative experience fraught with misdiagnoses, stigma, and depression and anxiety. Recent research demonstrates that mHealth technology may be one way that POTS patients can improve their experience in the healthcare system by providing objective data to their healthcare providers. Patients may also better take care of themselves through symptom monitoring and instant patient education via mHealth technology. The two study aims are: 1) Developing a mHealth app to improve the delay to diagnosis and the quality of life of POTS patients; and 2) Evaluate the usability and feasibility of the mHealth app and study design. To achieve these aims, researchers in this study will work with a programmer and leaders from the mHealth Application Modernization and Mobilization Alliance (MAMMA) and stakeholders (patients, caregivers, and providers) to co-design a mHealth app for POTS patients, including key educational components guided by the IDEA model, an instructional risk communication approach. A group of diagnosis-seeking POTS (n=20) patients will pilot test the app and provide feedback for improvement as well as evaluate its usability. Results from this study will allow researchers to acquire necessary data to apply for external funding to conduct a larger clinical trial to evaluate its influence on health outcomes, such as patient experience during visits with physicians, perceived stigma, and time to diagnosis. Type: Interventional Start Date: Feb 2024 |
Impaired Risk Awareness During Intoxication in DUI Offenders
Mark Fillmore
Alcohol Use
This study aims to test the efficacy of experiential-based training to increase DUI
offenders' perceptions or risk associated with alcohol use. expand
This study aims to test the efficacy of experiential-based training to increase DUI offenders' perceptions or risk associated with alcohol use. Type: Interventional Start Date: Feb 2022 |
Premolar Extractions for Obstructive Sleep Apnea in Children With Overjet
Mohamed Bazina
Obstructive Sleep Apnea
Malocclusion
This research aims to provide pediatric patients with polysomnography (a sleep study)
before and after orthodontic treatment to determine if the extraction of upper premolars
for treating excessive overjet results in an increase of the AHI (Apnea Hypopnea Index)
compared to similar patients treated1 expand
This research aims to provide pediatric patients with polysomnography (a sleep study) before and after orthodontic treatment to determine if the extraction of upper premolars for treating excessive overjet results in an increase of the AHI (Apnea Hypopnea Index) compared to similar patients treated without upper premolar extractions. Type: Observational Start Date: Sep 2021 |
Addressing Neuromuscular Deficits for Improved Outcomes in Ankle Rehabilitation
Phillip Gribble
Ankle Sprains
The purpose of this project is to compare a novel sensorimotor ankle rehabilitation
training (SMART) protocol for Lateral ankle sprains (LASs) against a standard of care
(SOC) protocol to determine if it is more successful at producing successful one-year
outcomes and lower rates of re-injury and i1 expand
The purpose of this project is to compare a novel sensorimotor ankle rehabilitation training (SMART) protocol for Lateral ankle sprains (LASs) against a standard of care (SOC) protocol to determine if it is more successful at producing successful one-year outcomes and lower rates of re-injury and improved health. This will address the identified needs for evidence-support and reintegration strategies to improve understanding of the management of patient rehabilitation strategies throughout the rehabilitation process following neuromusculoskeletal injury. The project will validate an innovative rehabilitation approach while providing metrics of success using a variety of clinical and innovative markers. Type: Interventional Start Date: Nov 2019 |
The Effects of Sex Hormones and Alcohol on Sleep
Lauren Whitehurst
Alcohol Use Disorder
Rates of heavy drinking and Alcohol Use Disorder (AUD) are increasing in women, but
research on alcohol-related harms in women - including alcohol's impact on sleep - has
been minimal. Numerous studies in men show that alcohol impairs sleep, and preliminary
evidence suggests that women may be even1 expand
Rates of heavy drinking and Alcohol Use Disorder (AUD) are increasing in women, but research on alcohol-related harms in women - including alcohol's impact on sleep - has been minimal. Numerous studies in men show that alcohol impairs sleep, and preliminary evidence suggests that women may be even more sensitive to alcohol-disrupted sleep due to their sex hormones, which fluctuate across both their menstrual cycles and their reproductive lifespans. This study will investigate the influence of sex, menstrual cycle phase, and sex hormones on alcohol-disrupted sleep in adults ages 21-45. Healthy women and men will complete two sets of placebo-controlled lab sessions, during the mid-follicular and late luteal phases of female participants' menstrual cycles. During these sessions, participants will receive a dose of alcohol or a placebo (saline) and they will then be monitored (with polysomnography) while they sleep. At-home sleep and alcohol use will also be measured through actigraphy, daily sleep and wake diaries, and alcohol wrist sensors. Investigators hypothesize that women will show greater disruption of sleep following alcohol use or administration than men, and that alcohol-disrupted sleep will be more pronounced in the late luteal phase compared to the mid-follicular phase. Investigators also expect that estradiol will be negatively associated with alcohol-disrupted sleep, whereas progesterone will be positively associated with alcohol-disrupted sleep. Type: Interventional Start Date: Jan 2024 |
NM Balance Regulation With ULLS and Loss of Sleep
Lance Bollinger
Muscle Weakness
Quadriceps Muscle Atrophy
Sleep Disturbance
The goal of this trial is to learn about how restricted sleep and not bearing weight on
the leg affects muscle strength and posture control. Participants will walk exclusively
on one leg, sleep at differing intervals, and complete posture tests, muscle strength
tests, and muscle imaging. Researcher1 expand
The goal of this trial is to learn about how restricted sleep and not bearing weight on the leg affects muscle strength and posture control. Participants will walk exclusively on one leg, sleep at differing intervals, and complete posture tests, muscle strength tests, and muscle imaging. Researchers will compare adequate sleep and restricted sleep to see if muscle strength and posture are affected. Type: Interventional Start Date: Aug 2023 |
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
Johns Hopkins University
Intracerebral Hemorrhage
This first-in-patient phase 2a pilot study will assess the safety and tolerability of
MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH). expand
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH). Type: Interventional Start Date: Oct 2022 |
Mechanisms for Activation of Beige Adipose Tissue in Humans
Philip Kern
PreDiabetes
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist
marketed for overactive bladder. This trial will assess the effects of mirabegron on
glucose tolerance and adipose tissue in prediabetic patients expand
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients Type: Interventional Start Date: Dec 2020 |
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Rachel Miller
Cancer
This is a substudy (Part 2) of a larger two-part clinical trial including both
observational and therapeutic (interventional) cohorts to assess the progression free
survival ratio of patients treated with a targeted therapy based on genomic analysis
results and recommendation by the Markey Cancer C1 expand
This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB). Type: Interventional Start Date: Apr 2017 |
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
University of Calgary
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection
Hemolytic-Uremic Syndrome
The objective of this study is to determine if early high volume intravenous fluid
administration (hyperhydration) may be effective in mitigating or preventing
complications of shiga toxin-producing E. coli (STEC) infection in children and
adolescents when compared with traditional approaches (cons1 expand
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management). Type: Interventional Start Date: Sep 2022 |
Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and1
Francis Farhadi
Spinal Cord Stimulation
Electric Stimulation Therapy
Traumatic Spinal Cord Injury
Cervical Myelopathy
The study will be a non-randomized, non-blinded pilot study to analyze the safety and
feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The
aim is to include 30 total patients, 10 patients in each of 3 groups:
1. Non-traumatic spinal cord injury (ntSCI) with d1 expand
The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The aim is to include 30 total patients, 10 patients in each of 3 groups: 1. Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy and offered surgical intervention. 2. Early tSCI screened during the hospital admission when cervical/thoracic spinal injury was diagnosed. 3. Delayed tSCI (control) screened 6-24 months after acute cervical/thoracic spinal injury. Type: Interventional Start Date: Oct 2024 |
Creating VIP Corps to Reduce Maternal Deaths
Ann Coker
Maternal Morbidity and Mortality
The goal of this observational study is to create and rigorously evaluate a violence
intervention and prevention corps (VIP Corps) training using a randomized controlled
trial among undergraduate and professional students; and to develop a novel maternal
injury surveillance system (MISS) to complem1 expand
The goal of this observational study is to create and rigorously evaluate a violence intervention and prevention corps (VIP Corps) training using a randomized controlled trial among undergraduate and professional students; and to develop a novel maternal injury surveillance system (MISS) to complement an existing maternal violent death registry in Kentucky. Type: Interventional Start Date: Sep 2023 |
Reinforcing Effects of Marijuana and Opioids
Shanna Babalonis, PhD
Marijuana Use
Opioid Use
The primary goals of this study are to examine 1) marijuana modulation of oxycodone
self-administration and 2) oxycodone modulation of marijuana self-administration, under
controlled conditions and across a range of doses for each drug. expand
The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug. Type: Interventional Start Date: Aug 2023 |
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive1
AbbVie
Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and
efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with
platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate
receptor-alpha (FRα) expression. expand
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression. Type: Interventional Start Date: Dec 2022 |
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
Century Therapeutics, Inc.
R/R CD19-Positive B-Cell Malignancies
Indolent Non-Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety,
pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or
refractory cluster of differentiation (CD)19-positive B-cell malignancies. expand
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies. Type: Interventional Start Date: Jan 2023 |
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
University of Florida
Intracranial Arteriosclerosis
Stroke
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or
ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of
ischemic stroke, intracerebral hemorrhage, or vascular death. expand
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death. Type: Interventional Start Date: Aug 2022 |
tDCS and Inhibitory Control in PTSD
Gopalkumar Rakesh
Post Traumatic Stress Disorder
Large samples (~2,000/yr) of adult undergraduate students at a large southern university
will be pre-screened via the University of Kentucky SONA System (IRB#43626) to identify
and recruit adult female participants who report a history of IPV and probable PTSD to
participate in a one-day lab study.1 expand
Large samples (~2,000/yr) of adult undergraduate students at a large southern university will be pre-screened via the University of Kentucky SONA System (IRB#43626) to identify and recruit adult female participants who report a history of IPV and probable PTSD to participate in a one-day lab study. After completing an IRB-approved informed consent, participants will complete a brief psychiatric diagnostic interview and a battery of questionnaires. They will then complete three blocks of the Stop Signal Task (SST). Participants will be randomized (double-blind, stratified by PTSD diagnosis and psychotropic medication use) to receive 15-min of active or sham multifocal tDCS targeting the rIFG. tDCS will be delivered offline for 11.5-mins after block 1 of the SST and online for 3.5-mins during block 2 of the SST. Sham stimulation will be identical to active tDCS, but electrical current will only be ramped in/out at the beginning and end of the 15-mins. The third block of the SST will be completed after tDCS. Lastly, participants will complete a pictorial trauma-related symptom provocation task. Participants will be compensated with course credit. Type: Interventional Start Date: Oct 2023 |
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participant1
Kowa Research Institute, Inc.
Fuchs Endothelial Corneal Dystrophy
A study to assess the safety and efficacy of K-321 in participants with FECD after
descemetorhexis. expand
A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis. Type: Interventional Start Date: Mar 2023 |
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
AtriCure, Inc.
Ischemic Stroke
Systemic Embolism
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority
trial. The objective of this trial is to evaluate the effectiveness of left atrial
appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial
embolism in subjects undergoing cardiac1 expand
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke. Type: Interventional Start Date: Jan 2023 |
Thoracic-Lumbar Arthrodesis- Implanet Jazz
Francis Farhadi
Spondylolisthesis
Spinal Stenosis
Degenerative Disease
Establish a data repository of patients who have undergone single, two-, or three-level
lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System. expand
Establish a data repository of patients who have undergone single, two-, or three-level lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System. Type: Observational [Patient Registry] Start Date: Feb 2022 |
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Philip Kern
Pre-diabetes
Obesity
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in
improved glucose metabolism, including a reversal of prediabetes in obese,
insulin-resistant human research participants, and this is further improved by
combination therapy with tadalafil. The investigator will1 expand
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo. Type: Interventional Start Date: Dec 2021 |
Bevacizumab Treatment For Type 1 ROP
Jaeb Center for Health Research
Retinopathy of Prematurity
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and
has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in
these severe cases. Also unknown is the timing and extent of peripheral retinal
vascularization after low-dose bevacizumab1 expand
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I. Type: Interventional Start Date: May 2022 |
- Previous
- Next